reports
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare...
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Citi 2024 Global Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Wednesday, December 4, 2024, at 10:15 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Event...
iRhythm Data Presented at the American Heart Association 2024 Scientif...
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic impact of early arrhythmia detection in patients with type 2 diabetes and COPD SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) today announced the results of five new studies presented at the American Heart As...
Irhythm Technologies Inc: 2 directors
Two Directors at Irhythm Technologies Inc bought/sold 22,809 shares at between 75.160USD and 77.410USD. The significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthc...
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Wolfe Research 2024 Healthcare Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, November 19, at 9:50 am Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Events ...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifica...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA 510(k)-cleared enhancements will be available in 2025 SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administrat...
iRhythm Technologies Announces Third Quarter 2024 Financial Results
iRhythm Technologies Announces Third Quarter 2024 Financial Results SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2024. Third Quarter 2024 Financial Highlights Revenue of $147.5 million, an 18% increase compared to third quarter 2023Gross margin of 68.8%, a 260-basis point increase compared to third quarter 2023Unrestricted cash, cash equivalents and marketable securities of $...
Newly Published Research Shows 14-Day Monitoring Detected Almost Three...
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting about 1 in 500 people and is one of the leading causes of sudden cardiac death (SCD) in people under 35, including among athletes.1NSVT (nonsustained ventricular tachycardia), a known marker for increased risk of SCD in HCM, was detected in nearly 50% of HCM patients in the study undergoing long-term continuous ambulatory ECG...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates ...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance for its 510(k) submi...
iRhythm Technologies to Report Third Quarter 2024 Financial Results on...
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024 SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the pr...
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio...
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trialZio ECG monitoring system previously received Japanese high medical needs designation, a unique distinction reflecting positive recommendation by the Japanese Heart Rhythm Society (JHRS)iRhythm will continue working towards reimb...
iRhythm Unveils Data Demonstrating Superior Real-World Performance of ...
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting iRhythm’s next-generation Zio® monitor demonstrated longer wear duration and analyzable time compared to the prior generation Zio® XT device.Longer wear duration and analyzable time may further improve diagnostic yield, building upon Zio XT service’s superior yield among ambulatory cardiac monitoring services as demonstrated by the prior CAMELOT study findings.1The Zio monitor ECG device has been worn by over 1 million patients since launching in late 2023.2 SAN FRANCISCO,...
iRhythm Technologies Enters License Agreement with BioIntelliSense for...
iRhythm Technologies Enters License Agreement with BioIntelliSense for Multiparameter Sensor Technology to be Used in Ambulatory Cardiac Monitoring iRhythm granted exclusive license to BioIntelliSense’s patented pulse oximetry, accelerometry and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring (ACM) market SAN FRANCISCO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has signed an exclusi...
iRhythm Technologies Announces Results of GUARD-AF Trial
iRhythm Technologies Announces Results of GUARD-AF Trial GUARD-AF trial results presented at European Society of Cardiology (ESC) Congress 2024Leveraging iRhythm’s Zio® patch-based long-term continuous monitoring (LTCM), GUARD-AF is the largest randomized trial in a primary care setting to evaluate the impact of screening for undiagnosed atrial fibrillation (AF) Screening with iRhythm’s Zio® XT1 LTCM led to increase in new diagnosis of AF (5.0% vs 3.3%) over an average follow-up of 15 months. No difference in stroke hospitalization vs usual care in the context of reduced statistical power d...
iRhythm Technologies Expands Global Reach with the Launch of Zio® Card...
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization Software) System (iRhythm’s advanced AI algorithm), and a comprehensive end-of-wear report reviewed and curated by certified cardiographic technicians.The next-generation Zio monitor LTCM provides up to 14 days of continuous, uninterrupted, patch-based ECG moni...
iRhythm Technologies to Participate in Upcoming Investor Conferences i...
iRhythm Technologies to Participate in Upcoming Investor Conferences in September SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will present at the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 3:20 pm Eastern TimeWells Fargo 2024 Healthcare Conference on Thursday, September 5, at 8:45 am Eastern TimeBaird 2024 Global Healthcare Confere...
iRhythm Technologies Announces Chief Financial Officer Transition
iRhythm Technologies Announces Chief Financial Officer Transition SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that Brice Bobzien, Chief Financial Officer, will step down for personal reasons effective August 31, 2024. He will be succeeded by Daniel Wilson, iRhythm’s current Executive Vice President of Corporate Development and Investor Relations. Mr. Bobzien has served as the CFO since 2022, and he will continue to serve the Company ...
iRhythm Technologies Announces Second Quarter 2024 Financial Results
iRhythm Technologies Announces Second Quarter 2024 Financial Results SAN FRANCISCO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2024. Second Quarter 2024 Financial Highlights Revenue of $148.0 million, a 19.3% increase compared to second quarter 2023Gross margin of 69.9%, a 40-basis point increase compared to second quarter 2023Unrestricted cash, cash equivalents and marketable securities of $56...
iRhythm Technologies to Report Second Quarter 2024 Financial Results o...
iRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024 SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2024 after the close of trading on Thursday, August 1, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the prese...
iRhythm Technologies Achieves Significant Operational Milestone with L...
iRhythm Technologies Achieves Significant Operational Milestone with Launch of Initial Phase of Manufacturing Automation SAN FRANCISCO, June 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings. In t...
iRhythm Technologies to Present at the 2024 Truist Securities MedTech ...
iRhythm Technologies to Present at the 2024 Truist Securities MedTech Conference SAN FRANCISCO, June 04, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming Truist Securities MedTech Conference. iRhythm’s management is scheduled to participate in a fireside chat on Tuesday, June 18, at 9:20 a.m. Eastern Time. Interested parties may access a live and archived webcast of the event on the “Events & Presentations” s...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.